Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseRole of chemotherapy in Hodgkin's lymphoma.A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.Advanced hodgkin lymphoma: a new era of therapy.Hodgkin's lymphoma therapy: past, present, and future.Hodgkin disease-an ever-evolving therapy.Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FuturePrognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.FDG-PET/CT based response-adapted treatment.FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaEarly interim PET scan in Hodgkin lymphoma: where do we stand?Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.Hodgkin's lymphoma: current treatment strategies and novel approaches.Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical TrialsReport of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010.Chemotherapy only for localized Hodgkin lymphoma.Management of children with high-risk Hodgkin lymphoma.PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.Risk-adapted strategies for the treatment of Hodgkin lymphoma.PET-directed therapy in Hodgkin lymphoma: Ready for prime time?The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.hENT1 and Hodgkin lymphoma: not just crossing the channel.A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved.Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
P2860
Q26750993-D31B5FC6-C086-4AC7-BE40-2FFCF5BB3DF6Q26858893-0083F8AC-10BB-4C1D-97C6-1451EE047B9BQ33761103-81422C3F-3AD4-4691-9E7B-D09F72A311E8Q33952842-BEA18A3D-8769-43DE-B6BF-6E94EEE1D479Q34194160-828C9CEE-AA22-4EE8-A939-2A39690922B0Q34296914-B4A6FC6A-AD3D-4D59-81B5-A79BFB6DD4D1Q34463426-0857D875-C52F-4D60-B716-0B8498D3D535Q34495333-812DE2A5-46FF-4A5A-9B14-FB4A117D3AB0Q34610653-19A61090-21BD-4029-8B09-57E55F7F8860Q35038852-1A985155-0EA3-46C5-A3A9-29F1E7A12DDCQ35232775-7031F7F1-26EF-44BC-B2EE-AEC1FDE8CA39Q36286595-92C0C88A-B506-4EC0-BF74-C42FE36371C7Q36838768-5CBB6FD8-55A1-40A6-8084-7A8AE50685A3Q36969748-0EBDA649-7335-4B0C-AA51-0F58C9CA3EC3Q37132894-A51A38EA-CC70-4FA3-B392-B4601312B66BQ37621398-BCEA068B-A066-4887-A0B7-C304B6BF1762Q37788240-6D98B3CF-393A-4E68-95B8-67C90FC162D1Q37810114-6308392E-F3FE-49AF-8F68-23549BC5CF18Q37821961-910A4F02-0AE5-442B-9088-981CFFDC9273Q37828408-4281C3C2-66E8-4C65-9C1D-D9B9282746F2Q37857870-68EC65C9-6FEE-4957-985F-36B1A31BCD94Q37888802-2A91913C-E0EF-489A-8DB0-2E25B26ED544Q37970408-BB642E0F-9AAE-4871-85F0-85E3107CB571Q38018865-17B9C159-5CA0-4C41-95DD-A172991D07DCQ38591137-22125769-6CB2-45CF-9620-383FE3C02AC0Q38608555-55BA4330-F287-4328-9E80-F86E2A82B980Q45428337-DD13D127-3DD3-40E7-A0D1-2D2FD82CFABDQ47565224-DB38BDF2-D010-4DFE-A8B0-FCC19E6EC444Q51408117-E31C6940-CE3B-4700-9DD5-CD5CCE93222EQ53145770-1376B0DE-3301-405D-BC3E-3B4828BD43F9
P2860
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@en
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@nl
type
label
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@en
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@nl
prefLabel
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@en
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@nl
P2093
P1433
P1476
Risk-adapted BEACOPP regimen c ...... with no impairment of outcome.
@en
P2093
Diana Libster
Eldad J Dann
Irit Avivi
Jacob M Rowe
Mark Kirschbaum
Menachem Ben-Shachar
Nissim Haim
Odelia Goor
Rachel Bar-Shalom
P304
P356
10.1182/BLOOD-2006-04-019901
P407
P577
2006-10-03T00:00:00Z